Larimar Therapeutics, Inc. (LRMR)
NASDAQ:LRMR
LRMR Analyst Ratings
Strong Buy
5 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
LRMR Stock 12 Month Forecast
Average Price Target
$13.90
▲(190.19% Upside)
| Highest Price Target$25.00 | Average Price Target$13.90 | Lowest Price Target$4.50 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
LifeSci Capital
$25
Buy
421.92%
Upside
Reiterated
04/01/26
Nomlabofusp’s Manageable Risk, Strong Efficacy Signals, and Significant FA Market Upside Underpin Buy Rating on LRMRAhead of topline data in 2Q26 and a planned June 2026 BLA submission seeking accelerated approval, we surveyed up to 24 US-based neurologists and cardiologists who collecv ely manage 267 Friedreich's Ataxia paen ts annually. We aimed to be er understand the potenal for LRMR’s nomlabofusp, a frataxin protein replacement therapy, to address unmet needs in FA, as well as physicians’ percepons of the therapy’s anaphylaxis rate. Key takeaways from physician responses on efficacy expectaons, anaphylaxis tolerability, and compev e posioning f ollow. Anaphylaxis risk considered manageable, not disqualifying. When asked about perceived manageability of anaphylaxis (based on data to date), physicians were split between anaphylaxis being highly manageable (46% rated 7-to-10) and moderately manageable (50% rated 4-to-6), which is encouraging, in our opinion (Figure 6).
Wedbush
$12→$13
Buy
171.40%
Upside
Reiterated
03/20/26
Citi
$14
Buy
192.28%
Upside
Reiterated
03/20/26
William Blair
$4.5
Buy
-6.05%
Downside
Reiterated
03/19/26
Truist Financial
―
Buy
―
Reiterated
11/06/25
Oppenheimer
$21
Buy
338.41%
Upside
Reiterated
11/06/25
Citizens JMP
$18
Buy
275.78%
Upside
Reiterated
10/06/25
Robert W. Baird
$10→$7
Buy
46.14%
Upside
Reiterated
09/30/25
Leerink Partners
$25
Buy
421.92%
Upside
Reiterated
09/30/25
Guggenheim
$26
Buy
442.80%
Upside
Reiterated
09/29/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
LifeSci Capital
$25
Buy
421.92%
Upside
Reiterated
04/01/26
Nomlabofusp’s Manageable Risk, Strong Efficacy Signals, and Significant FA Market Upside Underpin Buy Rating on LRMRAhead of topline data in 2Q26 and a planned June 2026 BLA submission seeking accelerated approval, we surveyed up to 24 US-based neurologists and cardiologists who collecv ely manage 267 Friedreich's Ataxia paen ts annually. We aimed to be er understand the potenal for LRMR’s nomlabofusp, a frataxin protein replacement therapy, to address unmet needs in FA, as well as physicians’ percepons of the therapy’s anaphylaxis rate. Key takeaways from physician responses on efficacy expectaons, anaphylaxis tolerability, and compev e posioning f ollow. Anaphylaxis risk considered manageable, not disqualifying. When asked about perceived manageability of anaphylaxis (based on data to date), physicians were split between anaphylaxis being highly manageable (46% rated 7-to-10) and moderately manageable (50% rated 4-to-6), which is encouraging, in our opinion (Figure 6).
Wedbush
$12→$13
Buy
171.40%
Upside
Reiterated
03/20/26
Citi
$14
Buy
192.28%
Upside
Reiterated
03/20/26
William Blair
$4.5
Buy
-6.05%
Downside
Reiterated
03/19/26
Truist Financial
―
Buy
―
Reiterated
11/06/25
Oppenheimer
$21
Buy
338.41%
Upside
Reiterated
11/06/25
Citizens JMP
$18
Buy
275.78%
Upside
Reiterated
10/06/25
Robert W. Baird
$10→$7
Buy
46.14%
Upside
Reiterated
09/30/25
Leerink Partners
$25
Buy
421.92%
Upside
Reiterated
09/30/25
Guggenheim
$26
Buy
442.80%
Upside
Reiterated
09/29/25
Best Analysts Covering Larimar Therapeutics
3 Months
xxx
Success Rate
8/11 ratings generated profit
Average Return
+23.51%
reiterated a xxx
rating 18 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 72.73% of your transactions generating a profit, with an average return of +23.51% per trade.
1 Year
Success Rate
8/11 ratings generated profit
Average Return
+22.85%
reiterated a buy rating 18 days ago
Copying Myles Minter's trades and holding each position for 1 Year would result in 72.73% of your transactions generating a profit, with an average return of +22.85% per trade.
2 Years
xxx
Success Rate
8/11 ratings generated profit
Average Return
+28.24%
reiterated a xxx
rating 18 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 72.73% of your transactions generating a profit, with an average return of +28.24% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
LRMR Analyst Recommendation Trends
Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
5
2
4
7
8
Buy
3
2
1
2
2
Hold
1
20
20
25
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
9
24
25
34
16
Each month's total comprises the sum of three months' worth of ratings.
LRMR Financial Forecast
LRMR Stock Forecast FAQ
What is LRMR’s average 12-month price target, according to analysts?
Based on analyst ratings, Larimar Therapeutics, Inc.’s 12-month average price target is 13.90.
What is LRMR’s upside potential, based on the analysts’ average price target?
Larimar Therapeutics, Inc. has 190.19% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is LRMR a Buy, Sell or Hold?
Larimar Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
What is Larimar Therapeutics, Inc.’s price target?
The average price target for Larimar Therapeutics, Inc. is 13.90. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $25.00 ,the lowest forecast is $4.50. The average price target represents 190.19% Increase from the current price of $4.79.
The highest analyst price target is $25.00 ,the lowest forecast is $4.50. The average price target represents 190.19% Increase from the current price of $4.79.
What do analysts say about Larimar Therapeutics, Inc.?
Larimar Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
How can I buy shares of LRMR?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.